Abstract

Breast cancers show a lack of response to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), despite 30% of tumors expressing EGFR. The mechanism of this resistance is unknown; however, we have recently shown that Met kinase activity compensates for loss of EGFR kinase activity in cell culture models. Met has been implicated in the pathogenesis of breast tumors and therefore may cooperate with EGFR for tumor growth. Here we have found that EGFR phosphorylation and cell proliferation is in part regulated by Met expression. In addition, we found that Met constitutive phosphorylation occurred independent of the Met ligand hepatocyte growth factor (HGF). Ligand-independent Met phosphorylation is mediated by Met amplification, mutation, or overexpression and by Met interaction with other cell surface molecules. In SUM229 breast cancer cells, we found that Met was not amplified or mutated, however it was overexpressed. Met overexpression did not directly correlate with ligand-independent Met phosphorylation as the SUM229 cell line was the only Met expressing breast cancer line with constitutive Met phosphorylation. Interestingly, Met expression did correlate with EGFR expression and we identified an EGFR/Met complex via co-immunoprecipitation. However, we only observed Met constitutive phosphorylation when c-Src also was part of this complex. Ligand-independent phosphorylation of Met was decreased by down regulating EGFR expression or by inhibiting c-Src kinase activity. Lastly, inhibiting EGFR and Met kinase activities resulted in a synergistic decrease in cell proliferation, supporting the idea that EGFR and Met functionally, as well as physically interact in breast cancer cells to regulate response to EGFR inhibitors.

Introduction

Epidermal growth factor receptor (EGFR) is a tyrosine kinase receptor shown to be mechanistically involved in cell growth and survival (reviewed in [1]). Ligand activation of EGFR results in homo- and hetero-dimerization with other members of the EGFR family of receptor (reviewed in [1]). This dimerization enables EGFR to autophosphorylate, resulting in the recruitment of signaling proteins to the receptor (reviewed in [1]). Approximately 30% of human breast tumors overexpress EGFR, and this overexpression correlates with a loss of estrogen responsiveness and a poor prognosis [2-5]. Despite strong correlative evidence from human breast tumors, transgenic mouse models have clearly demonstrated that overexpression of the EGFR alone is insufficient for tumor formation [6]. EGFR tyrosine kinase inhibitors (TKIs) are in clinical use in lung and pancreatic cancers, but have yet to demonstrate efficacy in breast cancer. We and others have recently identified the receptor tyrosine kinase Met as a key regulator of EGFR tyrosine kinase inhibitor resistance in cancer [7,8].

Met also is overexpressed in breast cancer cells and human breast tumors and its expression correlates with EGFR expression in basal type breast cancers [9-11]. Met or hepatocyte growth factor receptor is characterized as a receptor tyrosine kinase [12]. However, unlike EGFR, there are two broad mechanisms of Met activation: ligand-dependent and ligand-independent. In the mammary gland, ligand-dependent activation of Met involves the paracrine production of HGF by stromal cells, including fibroblasts [13]. Ligand-independent activation of Met has been shown to occur through a number of mechanisms, including mutation of Met, constitutive dimerization of Met associated with overexpression, pathway activation via hypoxic conditions, transactivation by other membrane proteins (including EGFR), and loss of negative regulators [14].
We have previously shown that the kinase activity of Met, in part, regulates EGFR tyrosine phosphorylation and growth in the absence of EGFR tyrosine kinase activity. Here we have identified a physical and functional interaction between EGFR and Met. Specifically, we found that EGFR tyrosine phosphorylation and growth were in part dependent on the expression of Met. We also found that neither HGF mRNA nor protein was expressed, suggesting a ligand-independent mechanism of Met phosphorylation. In that regard, Met was not amplified or mutated in SUM229 cells. The protein expression of Met was increased in the SUM229 cells, yet an increase in protein expression did not correlate with ligand-independent Met phosphorylation. Instead, we found that EGFR and Met co-immunoprecipitated in the SUM229 cells both in the absence and in presence of gefitinib and down regulation of EGFR expression decreased Met constitutive phosphorylation, again supporting a physical and functional interaction between EGFR and Met. Interestingly, c-Src was part of the EGFR/Met complex when Met was constitutively phosphorylated and inhibiting c-Src kinase activity also decreased Met phosphorylation. Taken together, these data suggest that EGFR and Met interact both physically and functionally and that the interaction is independent of the kinase activities of both molecules and that this interaction promotes EGFR TKI resistance via constitutive phosphorylation of Met.

**Results**

**Met expression regulates EGFR tyrosine phosphorylation and growth in the presence of gefitinib**

We have previously shown that constitutive phosphorylation of Met contributes to EGFR TKI resistance in breast cancer and that decreasing Met kinase activity, decreased EGFR tyrosine phosphorylation and proliferation in the presence of an EGFR tyrosine kinase inhibitor [7]. However, to determine if the expression of Met is required for EGFR tyrosine phosphorylation and growth in the presence of EGFR TKIs, we used lentiviral encoding shRNA constructs targeting Met. Using this method, we were able knockdown Met to approximately 40% of its endogenous expression level (Fig. 1A; Met panel). When these cells containing the knocked down Met were analyzed for EGFR tyrosine phosphorylation and proliferation in the presence of EGFR TKIs, we observed a decreased in EGFR tyrosine phosphorylation (Fig. 1A; PTyr panel). This decrease in EGFR overall tyrosine phosphorylation appeared to be mediated by a decrease in the phosphorylation of tyrosines 1068, 1148, and 1173 (Fig. 1A). Importantly, when the Met knockdown cells were analyzed for cell proliferation in the presence of gefitinib, an 80% decrease in cell proliferation was observed (Fig. 1B). These data suggest that downregulating Met expression sensitizes cells to EGFR TKIs by decreasing EGFR tyrosine phosphorylation and proliferation.

**Met is not genomically amplified but is overexpressed in EGFR expressing breast cancer cells**

The mechanism of Met constitutive phosphorylation in SUM229 breast cancer cells is unknown. It was previously reported that under conditions of acquired resistance to gefitinib in a lung cancer cell line, Met becomes genomically amplified and overexpressed [8]. Therefore, we analyzed array comparative genomic hybridization data to determine if Met was amplified in the SUM229 cells [15,16]. We found that Met was not amplified in SUM229 cells as determined by statistical analysis using circular binary segmentation, which indicated that, the copy number of MET was not more than 1.3 fold (data not shown). In addition, we sequenced the Met juxtamembrane and kinase domain regions previously shown to be mutated and mediate constitutive activation of Met in renal cancers [17]. No mutations were detected in Met from cDNA prepared from SUM229 cells (data not shown). Lastly, to determine if Met protein expression was increased in SUM229 cells we compared protein
lysates from SUM229 cells with lysates from a panel of twenty breast cancer cell lines and two non-malignant mammary epithelial cell lines (Fig. 2A). From this analysis, we found that Met protein was expressed in 50% of the breast cancer cell lines, yet only the SUM229 cell line contained constitutively phosphorylated Met (Fig. 2B).

**Met constitutive phosphorylation occurs independent of ligand in EGFR TKI resistant breast cancer cells**

To determine if constitutive phosphorylation of Met is mediated by its ligand, HGF, we first determined the amount of HGF present in SUM229 cells from both cell lysates and conditioned media. We were unable to detect HGF expression either in the cell lysate (Fig. 3A) or in conditioned media (Fig. 3B). Lysates and conditioned media from cells engineered to overexpress HGF were used as positive controls (Figs. 3A and 3B). These results were not unexpected, as HGF is not normally produced as an autocrine factor in normal epithelial nor in carcinomas [18]. However, to eliminate the possibility of a small amount of HGF contributing to the constitutive phosphorylation of Met, we used an HGF neutralizing antibody to prevent HGF from binding to Met. In the SUM149 cells where Met is not constitutively phosphorylated, we added exogenous HGF to stimulate Met phosphorylation and found that the neutralizing antibody decreased HGF-mediated Met tyrosine phosphorylation (Fig. 4; left panel). Yet in the SUM229 cells where Met is constitutively phosphorylated, the HGF neutralizing antibody had no effect on Met phosphorylation (Fig. 4; right panel). Therefore, Met is activated by a ligand-independent mechanism in SUM229 cells.

**EGFR associates with Met in EGFR TKI resistant breast cancer cells**

Ligand-independent activation of Met has been shown to occur through association with co-receptors. These co-receptors include molecules involved in adhesion, such as integrins and CD44, receptors known as semaphorins or plexins, and receptor tyrosine kinases, such as EGFR and Ron [19]. Therefore, to determine if EGFR and Met have the ability to co-associate, we immunoprecipitated lysates from SUM149 or SUM229 cells using EGFR or Met antibodies (as well as an isotype antibody control) and immunoblotted using EGFR or Met antibodies. We found that EGFR and Met did indeed co-immunoprecipitate both in SUM149 and SUM229 cells (Fig. 5A). Our previous work found that Met contributed to EGFR tyrosine phosphorylation in the presence of an EGFR TKI [7]. We hypothesized that this was a direct phosphorylation that occurred...
via EGFR and Met association. To validate this hypothesis we treated SUM149 and SUM229 cells with gefitinib and repeated the co-immunoprecipitation experiment. As predicted, we found that EGFR and Met remained associated independent of EGFR tyrosine kinase activity (data not shown). These results suggest that Met may be mediating EGFR phosphorylation through co-association leading to conformation changes in both receptors and that the association between EGFR and Met may regulate the kinase activity of Met. However, because this association is observed in cells without ligand-independent Met phosphorylation we looked for another kinase associating with the EGFR/Met complex in SUM229 cells. We identified c-Src associating with the EGFR in the immunoprecipitation complex in the SUM229 cells, but not the gefitinib sensitive SUM149 cells (Fig. 5A). These data complement our previous studies demonstrating a role for c-Src in phosphorylating EGFR in the absence of EGFR kinase activity [7].

To determine if the formation of the co-precipitation complex was regulating ligand-independent Met phosphorylation, we used shRNA to downregulate EGFR expression and found that decreasing EGFR expression, thereby decreasing EGFR and Met association, reduced Met phosphorylation (Fig. 5B). In addition, inhibiting c-Src kinase activity with the small molecule kinase inhibitor dasatinib also reduced Met phosphorylation (Fig. 5C). Therefore, it can be concluded that breaking apart the EGFR/Met association and reducing the contribution of c-Src kinase activity by decreasing EGFR expression, diminished Met constitutive phosphorylation. Thus, decreasing EGFR expression should abrogate the growth of SUM229 cells. In fact, knocking down EGFR expression decreased cell proliferation over a 7-day period by 80% (Fig. 5D). These data suggest that EGFR has the ability to act as a scaffolding protein to link Met and c-Src.

**Figure 5** EGFR and Met association independent of EGFR kinase activity. (A) SUM149 or SUM229 cells were treated with 0.5 μM gefitinib or DMSO control for 30 min. Cells were lysed and immunoprecipitated with anti-EGFR, anti-Met, and anti-IgG. Whole cell lysates were used as a control. Immunoprecipitates were separated by SDS-PAGE, transferred, and immunoblotted using anti-EGFR, anti-Met, or anti-c-Src antibodies. (B) SUM229 cells were incubated with EGFR shRNA lentiviral particles for 72 hrs. Lysates were prepared and separated by SDS-PAGE. Membranes were immunoblotted with anti-pMet, anti-Met, anti-EGFR, and β-actin. (C) SUM229 cells were treated with increasing concentrations of dasatinib for 2 hrs. Lysates were prepared and immunoblotted with anti-pMet, anti-Met, and anti-pSrc antibodies. (D) SUM229 cells were incubated with EGFR shRNA lentiviral particles for 24 hrs and then treated with puromycin to select for virus expressing cells. After the puromycin was added for 24 hrs, the cells were grown for 7 days at which point cell numbers were determined via Coulter counting.

**EGFR and Met inhibitors act synergistically to abrogate EGFR TKI resistant breast cancer cell growth**

The association of EGFR and Met and their mutual regulation of each other in the absence of EGFR kinase activity and Met ligand suggests that inhibiting the kinase activity of the molecules individually may be insufficient to abrogate cell growth. We previously published proliferation assays with the combination of EGFR and Met inhibitors and found when SUM229 cells were treated with this combination of inhibitors, cell proliferation was arrested [7]. However, we did not determine if this decrease in cell proliferation was a result of synergism between the two drugs. Therefore, we used cell viability assays to assess the IC50 values for gefitinib and SU11274 (a Met inhibitor) and performed synergy analysis using an isobologram. We found the calculated IC50 for gefitinib to be approximately 12.2 μM and the IC50 for SU11274 to be 4.8 μM (Figure 6). Adding increasing concentrations of SU11274 to gefitinib treated cells reduced the IC50 of the cells to gefitinib. CI values were calculated and values under 1 are considered synergistic. When the SUM229 cells were treated with gefitinib and SU11274, the calculated CI values were less than 1. Specifically, at 1.25 μM SU11274 the mean CI value was 0.619 ± 0.038 and at 2.5 μM SU11274 the CI value was 0.781 ± 0.025. Therefore, EGFR and Met kinase inhibitors interact synergistically in the SUM229 cells.
mRNA detection using in situ hybridization \[23,24\]. In contrast, several groups have suggested that HGF is expressed in the breast tumor cells via mRNA detection using cell culture models may overlook important contributions of the tumor microenvironment to EGFR/Met crosstalk in breast cancer. In that regard, we have previously shown that the SUM149 cells responded to exogenous HGF treatment by phosphorylating Met and recovering some EGFR tyrosine phosphorylation and growth in the presence of EGFR TKIs \[7\].

Our data support a ligand-independent mechanism of Met activation in SUM229 breast cancer cells. Lai and colleagues summarized multiple mechanisms for ligand-independent Met activation \[14\]. Specifically, Met amplification, mutation, and truncation, overexpression of Met leading to constitutive dimerization, pathway activation by hypoxia, transactivation by other receptors, and loss of negative regulators have been shown to induce ligand-independent Met activation \[14\]. Our data clearly demonstrate that Met is not amplified, mutated, or truncated in SUM229 cells. However, we do find that Met is overexpressed at the protein level and that EGFR associates with Met. We have therefore provided evidence for the interaction and dependence of Met phosphorylation by EGFR expression and kinase activation.

Both physical and functional associations of EGFR and Met have been shown to crosstalk functionally. EGFR has been shown to activate Met in lung and thyroid cancer cells as well as in the development of the kidney, hepatocytes, and retina \[27-32\]. This is the first report of EGFR and Met physically interacting and EGFR regulating Met activation in the absence of HGF in breast cancer.

Cellular mechanisms of resistance to EGFR small molecule inhibitors have best been studied in lung cancers containing EGFR sensitizing mutations. Using clinical specimens from patients with non small cell lung cancers that recurred after treatment with EGFR inhibitors, 50% of patients have acquired an additional mutation, T790 M, which creates an EGFR that no longer responds to EGFR inhibition \[33\]. In addition, 20% of EGFR inhibitor refractory lung cancers have amplification of Met \[8,34\]. Other molecules such as Ras and IGF-IR also have been implicated in resistance to EGFR inhibitors \[35,36\]. The data provided in this report suggest that in addition to the identified resistance factors in lung cancer, Met activity may be a regulator of response to EGFR inhibitors in breast cancers.

Overall, our data provide evidence for a physical and functional interaction between EGFR and Met. This interaction regulates the phosphorylation of both EGFR
and Met such that each molecule is capable of mediating cellular responses independent of EGFR kinase activity. In addition, this EGFR kinase independent activity is in part mediated by c-Src activity. Therefore, the abrogation of the kinase activity of each molecule in combination provides intriguing evidence for dual EGFR and Met inhibitor studies in breast cancers.

**Materials and methods**

**Cell lines, culture conditions, and reagents**

The growth conditions for each cell line are as follows. SUM 52, SUM 149, SUM 159, SUM 185, SUM 225, and SUM 229 cells are grown in 5%IH media (Ham’s F-12 media, supplemented with 5% FBS, 1 μg/ml hydrocortisone, and 5 μg/ml insulin). SUM 1315 cells are grown in 5%IE media (Ham’s F-12 media, supplemented with 5% FBS, 10 ng/ml EGF, and 5 μg/ml insulin). SUM 44 and SUM 190 cells are grown in SF1H media (Ham’s F-12 media, supplemented with 1 μg/ml hydrocortisone, 5 μg/ml insulin, 5 mM ethanalamine, 10 mM HEPES, 5 μg/ml transferrin, 10 mM triodo-thyronine, 50 μM sodium selenite, and 5% BSA). SUM 102 and MCF10A cells are grown in SFIHE media (Ham’s F-12 media, supplemented with 1 μg/ml hydrocortisone, 5 μg/ml insulin, 10 ng/ml EGF, 5 mM ethanalamine, 10 mM HEPES, 5 μg/ml transferrin, 10 mM triiodo-thyronine, 50 μM sodium selenite, and 5% BSA). MCF7, SKBr3, T47 D, MDA-MB-231 and MDA-MB-468 cells are grown in DMEM media, supplemented with 1 μg/ml hydrocortisone, 1 mM sodium pyruvate, and 10% FBS). BT-20 cells are grown in Eagles+NEAA media (Eagle’s MEM with 2 mM L-glutamine and Earle’s BSS adjusted to contain 1.5 g/L sodium bicarbonate, 0.1 mM non-essential amino acids, 1 mM sodium pyruvate, and 10% FBS). BT-549 cells are grown in RPMI+L-GLUT(2 mM) media (RPMI-1640, supplemented to contain 1.5 g/L sodium bicarbonate, 4.5 g/L glucose, 10 mM HEPES, 1 mM sodium pyruvate, 0.023 IU/ml insulin, and 10% FBS). HCC 1937 and HCC 1954 cells are grown in RPMI+L-GLUT media (RPMI-1640 media with 2 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate, 4.5 g/L glucose, 10 mM HEPES, 1 mM sodium pyruvate, and 10% FBS). The SUM and HCC cells are cultured in 10% CO2 and the remaining cells are cultured in 5% CO2. All media are supplemented with 2.5 μg/ml amphotericin B and 25 μg/ml gentamicin.

Gefitinib was provided by AstraZeneca, SU11274 was purchased from EMD Biosciences (Gibbstown, NJ), and dasatinib was purchased by LC Laboratories (Woburn, MA). The HGF neutralizing antibody was a kind gift from George Vande Woude (VARI, Grand Rapids, MI). All other reagents were purchased from Thermo Fisher (Houston, TX) or Sigma (St. Louis, MO), unless indicated.

**Genetic analysis**

The genomic array CGH experiments were performed previously using the Agilent 44 K human genome CGH microarray chip [37,38](Agilent Technologies, Palo Alto, CA, USA). Circular binary segmentation analysis was used to determine changes in copy number [39].

**HGF ELISA**

One million cells were plated on 100 mm dishes and grown for 48 hours. The media was changed to serum free media and the cells were incubated for 72 hours. Conditioned media was collected from fibroblasts engineered to express HGF as a positive control. The HGF ELISA assay was performed as directed by the manufacturer (R&D Systems, Minneapolis, MN). Briefly, conditioned media was undiluted or diluted 1:2 and 1:10 and used to measure the amount of HGF using a standard curve.

**Immunoprecipitation and Immunoblotting**

Cells were plated at 1 million cells per 100 mm dish and growth for 48 hours. Cells were then lysed in CHAPS lysis buffer (10 mM CHAPS, 50 mM Tris, pH 8.0, 150 mM NaCl, and 2 mM EDTA with 10 μM NaOVA and 1× protease inhibitor cocktail (EMD Biosciences)). For immunoprecipitations 500 μg of lysate was precleared with 40 μl of protein A agarose beads (Millipore, Billerica, MA) for 30 min at 4°C. The supernatant was saved and added to 5 μl of mab-108 EGFR antibody (kind gift from Michael Weber, University of Virginia), Met antibody (Cell Signaling, Beverly, MA), or IgG isotype control antibody (Millipore) for 1 hr at 4°C. Immunoprecipitates were collected with the addition of 40 μl of protein A agarose beads for 30 min at 4°C and washed 2× with CHAPS and 1× with PBS. The protein was removed from the beads with 40 μl of hot 2× lameli buffer. Protein was separated by SDS-PAGE, transferred to Immunolin-P (Millipore) and immunoblotted for the indicated protein.

For immunoblotting, indicated amount of protein lysate was separated by SDS-PAGE and transferred to Immobol-in-P. Membranes were blocked in either 5% non-fat dry milk or 5% BSA for 1 hr at RT. The following primary antibodies were used in the experiments: anti-EGFR (Cell Signaling, 1:500), anti-Met (Cell Signaling, 1:500), anti-PY-HRP (Invitrogen, Carlsbad, CA, 1:5 000), anti-EGFR Y845 (Cell Signaling, 1:750), anti-EGFR Y992 (Cell Signaling, 1:500), anti-EGFR Y1045 (Cell Signaling, 1:500), anti-EGFR Y1068 (Cell Signaling, 1:500), anti-EGFR Y1086 (Cell Signaling, 1:500), anti-EGFR Y1148 (Cell Signaling, 1:500), anti-EGFR Y1173 (Cell Signaling, 1:750), anti-pMet (Cell Signaling, 1:500), anti-HGF (IBL, 1:500), anti-Src (Cell Signaling, 1:1 000), and anti-β-actin (Sigma, 1:10 000). The antibodies were incubated overnight at 4°C, with the exception of the P1yr
antibody which was blocked overnight and incubated with antibody for 1 hr. The membranes are then washed with TBS-T (TBS + 0.1% Tween-2) three times for 10 min each followed by incubation with the corresponding secondary antibody, and another series of three washes. Incubation with enhanced chemiluminescence (GE Biosciences, Piscataway, NJ) followed by exposure to film was used to detect the reactive bands. Each experiment was repeated at least three times and quantitated using densitometry.

**Lentiviral shRNA knockdown**

To downregulate EGFR and Met expression we used shRNA lentiviral particles using commercially available lentiviral constructs from OpenBiosystems (Huntsville, AL)(EGFR = TRCN0000121204 and Met = TRCN000121233). Twenty-four EGFR shRNA constructs and twelve Met shRNA constructs were screened and validated for EGFR or Met knockdown. At least three constructs were used in the studies for each protein with the data from the representative shRNA shown. The lentiviruses were packaged using a third generation lentiviral packaging system developed by Didier Trono and colleagues (Lausanne, Switzerland) and purchased from Addgene [40]. Specifically, Addgene plasmids pMLDg/pRRE (12251), pRSV-Rev (12253), and pMD2.G (12259) were transfected into HEK293T cells with the lentiviral vectors containing the shRNAs using FUGENE6 (Roche, Madison, WI). Cellular supernatant was collected on days 2 and 3 after transfection, pooled, and filtered. The lentivirus was titered using HEK293T cells incubated with increasing concentrations of virus with polybrene and selected for via the puromycin selection on the lentiviral vector. Colonies were counted and used to compare viral preps and between viruses for consistent titers used in experiments. For the SUM229 cells, equal amounts of virus was added to SUM229 cells in the presence of polybrene for four days prior to cell lysis.

**Cell proliferation assays**

For the proliferation assays the indicated breast cancer cells were plated in triplicate in 6-well plates at 35 000 cells per well (Day 0). The next day, the cells were treated with gefitinib every day for seven days at the indicated dosage. The number of cells was determined using a Coulter Counter on Days 1, 4, and 8. Each experiment was repeated at least twice and the graph represents the average and standard error of the mean at day 8.

For the MTS assays, cells were plated at 2 000 cells/well of a 96 well plate in triplicate. The indicated doses of gefitinib and SU11274 were added 24 hours later. The cells were incubated with the drugs for 72 hours at which time the MTS reagent was added per manufacture directions (Promega, Madison, WI) and read using a Dynex spectro-photometer. The experiment was repeated three times with error bars representing the SEM.

**Statistics**

Isobolograms were performed by determining the IC$_{50}$ values for gefitinib and SU11274 using Graph Pad Prism via standard MTS assay. The concentration of gefitinib used included 0.001, 0.1, 1, 5, 10, 50, and 100 μM. The concentrations of SU11274 used included 0.01, 0.1, 0.5, 1, and 5 μM. CI values were calculated using the following equation: (IC$_{50}$ combination/IC$_{50}$ gefitinib) + (concentration of SU11274/IC$_{50}$ SU11274). CI values were compared to 1.0 (CI value with 0 μM SU11274) by unpaired T tests.

**Conflict of Interest**

The authors declare that they have no competing interests.

**Authors’ contributions**

KLM performed the experiments for figures 1, 3, 4, 5, 6, Z-QY generated performed the array CGH and microarray data used to determine that Met was not amplified or overexpressed. RH analyzed the data generated by Zeng-Quan Yang to determine statistical significance. SPE contributed significant intellectual support to this manuscript as well as supports RH. JLB performed the experiments for figure 2 and assistant with some of the other experiments. She also wrote the manuscript and directed the project. All authors read and approved this manuscript.

**Acknowledgements**

We would like to thank Dr. Yubin Ge for assistance with the synergy experiments. This work was supported by Susan G. Komen for the Cure Career Catalyst Grant (KGO81416/JLB) and Department of Defense Oncogencic and Molecular Imaging Center (NOMIC) Grant (W81XWH-08-2-0160, SPE).

**Author Details**

1. Karmanos Cancer Institute at Wayne State University, John R. St, Detroit, MI 48201, USA. 2. Department of Pharmacology at Wayne State University, E. Canfield, Detroit, MI 48201, USA and 3. Department of Pathology at Wayne State University, Detroit, MI, 48201, USA.

Received: 5 May 2010 Accepted: 12 July 2010

**References**

1. Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, Burgess AW: Epidermal growth factor receptor: mechanisms of activation and signalling. Experimental Cell Research 2003, 284:31-53.
2. Koenders PG, Beek LV, Geurts-Moespot A, Heuvel JJ, Kienhuis CB, Benraad TJ: Epidermal growth factor receptor-negative tumors are predominantly confined to the subgroup of estradiol receptor-positive human primary breast cancers. Cancer Res 1991, 51:4544-4548.
3. Sainsbury JR, Fardond JR, Needham CK, Malcolm AJ, Harris AL: Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet 1987, 1:1398-1402.
4. Singletary SE, Baker FL, Spitzer G, Tucker SL, Tomaszewicz B, Brock WA, Ajani JA, Kelly AM: Biological effect of epidermal growth factor on the in vitro growth of human tumors. Cancer Res 1987, 47:403-406.
5. Toi M, Osaki A, Yamada H, Toge T: Epidermal growth factor receptor expression as a prognostic indicator in breast cancer, Eur J Cancer 1991, 27:977-980.
6. Brandt R, Eisenbrandt R, Leenders F, Zischiesche W, Rinas B, Juergensen C, Theuring F: Mammary gland specific eHEGF receptor transgene expression induces neoplasia and inhibits differentiation. Oncogene 2000, 19:2129-2137.
7. Mueller KL, Hunter LA, Ether SP, Boerner JL: Met and c-Src cooperate to compensate for loss of epidermal growth factor receptor kinase activity in breast cancer cells. Cancer Res 2008, 68:3314-3322.

8. Engelmann JA, Zeijlnnhuken M, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale OM, Xiao X, Christensen J, et al: MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316:1039-1043.

9. Camp RL, Rimm EB, Rimm DL: Met expression is associated with poor outcome in patients with axillary lymph node negative breast carcinoma. Wiley-Liss. 1999:2295-2269.

10. Ghousoub RAD, Dillon DA, D’Aquila T, Rimm EB, Fearon ER, Rimm DL: Expression of c-met is a strong independent prognostic factor in breast cancer. Wiley-Liss, 1998:1513-1520.

11. Beviglia Lucia, KMC-SLBLZRHK: Expression of the C-Met/HGF receptor in human breast carcinoma: Correlation with tumor progression. International Journal of Cancer 1997, 74:301-309.

12. Peschard P, Park M: From Tpr-Met to Met, tumorigenesis and tubes. Oncogene 2010, 26:1276-1285.

13. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF: Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003, 4:915-925.

14. Las AZ, Abella JV, Park M: Crosstalk in Met receptor oncogenesis. Trends Cell Biol 2009, 19:542-551.

15. Forozan F, Veldman R, Ammerman CA, Parsa NZ, Kallioniemi A, Kallioniemi OP, Ether SP: Molecular cyogenetic analysis of 11 new breast cancer cell lines. Br J Cancer 1999, 81:1328-1334.

16. Yang ZQ, Albertson D, Ether SP: Genomic organization of the 8p11-p12 amplon in three breast cancer cell lines. Cancer Genet Cytogenet 2004, 155:57-62.

17. Schmidt R, Duh F-M, Chen F, Kishida T, Glenn G, Choyke P, Scherer SW, Heelan RT, Kris MG, Varmus HE: KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005, 2:e17.

18. Nijman SN, Kobayashi S, Costa DB: Tyrosine kinase: can the challenge be met? Trends in Molecular Medicine 2005, 11:284-292.

19. Corso S, Cornoglio Pi, Giordano S: Cancer therapy: can the challenge be met? Trends in Molecular Medicine 2005, 11:284-292.

20. Nguyen KS, Kobayashi S, Costa DB: Acquisition resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin Lung Cancer 2009, 10:281-289.

21. Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, Ladanyi M, Zakowski MF, Heelan RT, Kris MG, Varmus HE: KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005, 2:e17.

22. Forozan F, Veldman R, Ammerman CA, Parsa NZ, Kallioniemi A, Kallioniemi OP, Ether SP: Molecular cyogenetic analysis of 11 new breast cancer cell lines. Br J Cancer 1999, 81:1328-1334.

23. Yang Z-Q, Albertson D, Ether SP: Genomic organization of the 8p11-p12 amplon in three breast cancer cell lines. Cancer Genet Cytogenet 2004, 155:57-62.

24. Schultz R, Vande Woude GF: Shh and the Hedgehog pathway. Cell 2005, 121:299-308.

25. Dahl RN, von Sprecher M, Petersen R, Christensen J, et al: MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316:1039-1043.

26. Scheving LA, Stevenson MC, Taylormore JM, Trauner P, Russell WE: Integral role of the EGFR receptor in HGF-mediated hepatocyte proliferation. Biochem Biophys Res Commun 2002, 290:197-203.

27. Balak MN, Gong Y, Riely GJ, Somwar R, Li AR, Zakowski MF, Chiang A, Yang G, Querellill O, Kris MG, et al. Novel D761Y and Common Secondary T790 M Mutations in Epidermal Growth Factor Receptor-Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors. Clinical Cancer Research 2006, 12:4694-4691.

28. Beviglia Lucia, KMC-SLBLZRHK: Expression of the C-Met/HGF receptor in human breast carcinoma: Correlation with tumor progression. International Journal of Cancer 1997, 74:301-309.

29. Peschard P, Park M: From Tpr-Met to Met, tumorigenesis and tubes. Oncogene 2010, 26:1276-1285.

30. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF: Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003, 4:915-925.

31. Las AZ, Abella JV, Park M: Crosstalk in Met receptor oncogenesis. Trends Cell Biol 2009, 19:542-551.

32. Forozan F, Veldman R, Ammerman CA, Parsa NZ, Kallioniemi A, Kallioniemi OP, Ether SP: Molecular cyogenetic analysis of 11 new breast cancer cell lines. Br J Cancer 1999, 81:1328-1334.

33. Forozan F, Veldman R, Ammerman CA, Parsa NZ, Kallioniemi A, Kallioniemi OP, Ether SP: Molecular cyogenetic analysis of 11 new breast cancer cell lines. Br J Cancer 1999, 81:1328-1334.

34. Yang Z-Q, Albertson D, Ether SP: Genomic organization of the 8p11-p12 amplon in three breast cancer cell lines. Cancer Genet Cytogenet 2004, 155:57-62.

35. Nguyen KS, Kobayashi S, Costa DB: Tyrosine kinase: can the challenge be met? Trends in Molecular Medicine 2005, 11:284-292.

36. Corso S, Cornoglio Pi, Giordano S: Cancer therapy: can the challenge be met? Trends in Molecular Medicine 2005, 11:284-292.

37. Nguyen KS, Kobayashi S, Costa DB: Tyrosine kinase: can the challenge be met? Trends in Molecular Medicine 2005, 11:284-292.

38. Nakasone S, Ueshima H, Takahashi K, Kato N, Okada Y, Ikeda Y, et al. Gene expression profiling of gastric cancer cell lines using microarrays. Cancer Res 2007, 67:5119-5128.

39. Nakasone S, Ueshima H, Takahashi K, Kato N, Okada Y, Ikeda Y, et al. Gene expression profiling of gastric cancer cell lines using microarrays. Cancer Res 2007, 67:5119-5128.

40. Tuck AB, Park M, Stermi EE, Boag A, Elliot BE: Coexpression of hepatocyte growth factor receptor and Met in human breast carcinoma. Am J Pathol 1994, 144:675-682.

41. Tuck AB, Park M, Stermi EE, Boag A, Elliot BE: Coexpression of hepatocyte growth factor receptor and Met in human breast carcinoma. Am J Pathol 1994, 144:675-682.

42. Jo M, Stolz DB, Esplen JE, Dorko K, Michalopoulos GK, Strom SC: Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells. J Biol Chem 2000, 275:8806-8811.

43. Guo A, Villen J, Kornhauser J, Lee KA, Stoklos MP, Rikova K, Possner A, Nardone J, Innocenti G, Wettstein R, et al. Signaling networks assembled by oncogenic EGFR and c-Met. Proc Natl Acad Sci USA 2008, 105:692-697.

44. Bergstrom JD, Westermark B, Heldin NE: Epidermal growth factor receptor signaling activates met in human anaplastic thyroid carcinoma cells. Exp Cell Res 2005, 299:293-299.

45. Piresnell SC, Stolz DB, Mars WM, Jo M, Michalopoulos GK, Strom SC: Modifications of the hepatocyte growth factor/c-Met pathway by constitutive expression of transforming growth factor-alpha in rat liver epithelial cells. Mol Carcinog 1997, 18:244-255.

46. Yamamoto N, Mammadova G, Song RX, Fukami Y, Sato K: Tyrosine phosphorylation of p145Met mediated by EGFR and Src is required for serum-independent survival of human bladder carcinoma cells. J Cell Sci 2006, 119:4623-4633.